48. Comparative Effectiveness of Intravenous Ketamine and Intranasal Esketamine in Clinical Practice
ฝัง
- เผยแพร่เมื่อ 14 พ.ย. 2023
- Ketamine has been redeveloped as a rapid-acting antidepressant for treatment-resistant depression (TRD). There is a paucity of literature comparing subanesthetic intravenous (IV) ketamine and US Food and Drug Administration (FDA)-approved intranasal (IN) esketamine for TRD in real-world clinical settings. We compared the efficacy and time to achieve remission/response with repeated ketamine and esketamine.